Please assess the completion status of the following clinical trial:

Trial Title: Gadoxetic Acid-MRI Versus Ultrasonography for the Surveillance of Hepatocellular Carcinoma in High-risk Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients with liver cirrhosis with the 1 year risk of HCC of 5% or higher meeting all of following criteria;~1. The evidence of cirrhosis of any etiology within 12 months prior to screening Definition of cirrhosis by any of following methods~   * 1) Histologically by liver biopsy;~  * 2) Non-histologically by evidence of portal hypertension in the presence of chronic liver disease;~     * Evidence of portal hypertension, including any of followings;~       1. The identification of splenomegaly on USG, CT, or MRI examinations with typical features of cirrhosis~      2. The identification of esophageal or gastric varices on endoscopic examination~2. High Risk Index (\>=2.33); Risk Index = 1.65 (if the prothrombin activity is \<=75%) + 1.41 (if the age is 50 years or older) + 0.92 (if the platelet count is \<=100x10(3)/mm3) + 0.74 (if the presence of anti-hepatitis C virus \[HCV\] or hepatitis B surface antigen \[HBsAg\] is positive).~3. Older than 20 years of age~4. Absence of previous or current history of HCC~5. Absence of HCC should be identified by liver USG, dynamic CT, or contrast-enhanced MRI within 6 months prior to screening~6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2~7. Patient is able to comply with scheduled visits, evaluation plans, and other study procedures.~8. Patient is willing to provide written informed consent~Exclusion Criteria:~Presence of any of following criteria;~1. Active or suspected cancer other than HCC, or a history of malignancy where the risk of recurrence is \>20% within 2 years~2. Child-Pugh score \>9~3. Significant medical comorbidities in which survival is predicted to be less than 3 years~4. Estimated glomerular filtration rate (GFR) \< 30 mL/min/1.73m2~5. Precautions for MRI (cardiac pacemaker, ferromagnetic implants, etc.)~6. Severe claustrophobia that may interfere with protocol compliance.~7. Any other condition which, in the opinion of the Investigator, would make the patient unsuitable for enrollment or could interfere with the completing the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HCC high-risk group (Type: None): Patients with liver cirrhosis with the 1-year risk of HCC of 5% or higher~; High Risk Index (\>=2.33)~Risk Index = 1.65 (if the prothrombin activity is \<=75%) + 1.41 (if the age is 50 years or older) + 0.92 (if the platelet count is \<=100x10(3)/mm3) + 0.74 (if the presence of anti-hepatitis C virus \[HCV\] or hepatitis B surface antigen \[HBsAg\] is positive).

Based on this trial design, predict the completion outcome and termination type (if applicable).